UB-VV500

UB-VV500 is an investigational in vivo CAR-T cell therapy being developed by Umoja Biopharma for the treatment of multiple myeloma. The specific target antigen for this therapy has not been publicly disclosed. UB-VV500 utilizes a chimeric antigen receptor T-cell (CAR-T) approach, where genetic material encoding a CAR is delivered directly into the patient to generate CAR-T cells in vivo, rather than modifying T cells ex vivo. This strategy aims to simplify manufacturing and potentially improve accessibility compared to traditional autologous CAR-T therapies. As of early 2025, UB-VV500 remains in preclinical development[1][2][4].